<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136247">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01989780</url>
  </required_header>
  <id_info>
    <org_study_id>JBCRG-M04</org_study_id>
    <nct_id>NCT01989780</nct_id>
  </id_info>
  <brief_title>Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive Human Epidermal Growth Factor Receptor 2(HER2)-Negative Breast Cancer</brief_title>
  <acronym>BOOSTER</acronym>
  <official_title>Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive HER2-negative Breast Cancer -BOOSTER Trial, a Multicenter Randomized Phase II Study-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Breast Cancer Research Group</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate optimal usage of bevacizumab to compare which is better, continuing bevacizumab
      and paclitaxel or switching to hormonal maintenance therapy followed by
      bevacizumab+paclitaxel after induction therapy of bevacizumab+paclitaxel.

      To examine biomarkers such as monitoring markers of study treatment as exploratory analysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to failure of strategy (TFS)</measure>
    <time_frame>3.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>2y Overall Survival rate</measure>
    <time_frame>3.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3.5years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival(PFS)</measure>
    <time_frame>3.5years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>3.5years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker(IMPACT assay Chips, whole blood, tumor tissue, Serum)</measure>
    <time_frame>3.5years</time_frame>
    <safety_issue>No</safety_issue>
    <description>vascular endothelial growth factor(VEGF)-A, VEGFR-2, VEGF-C, platelet derived growth factor(PDGF)-C, Soluble fms-like tyrosine kinase-1, VEGFR-3, Interleukin(IL)-8, Basic Fibroblast Growth Factor(FGFb), placental growth factor(PLGF), E-Selectin, intercellular adhesion molecule(ICAM)-1, neuropilin of Tumor tissue, single nucleotide polymorphism(SNP):VEGFR-1 and VEGF of whole blood DNA, angiotensin(ANG) and Apelin of serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety(Collection of adverse events)</measure>
    <time_frame>3.5years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>weekly paclitaxel + bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>weekly paclitaxel + bevacizumab followed by hormone therapy(Treatment of physician's choice) + bevacizumab then back to weekly paclitaxel + bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Aromasin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>leuprorelin acetate</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Leuplin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Histologically confirmed adenocarcinoma of the breast

          2. Female aged 20-75 years old at getting informed consent

          3. HER2 negative disease (IHC 0/1+ or 2+ with FISH negative)

          4. Documented estrogen receptor (ER) positive (&gt;=1% by IHC)

          5. Inoperative locally advanced or metastatic breast cancer at enrolment

          6. Performance status (ECOG): 0-1 at enrolment

          7. Life expectancy of at least 3 months from enrolment

          8. No prior systemic therapy for recurrent breast cancer (excluding hormone therapy)

          9. No prior neo and/or adjuvant chemotherapy with taxane or adjuvant setting with a
             disease-free interval from completion of the taxane treatment to metastatic diagnosis
             of &gt;= 12 months

         10. Patients with measurable lesion regarding with Response Evaluation Criteria in Solid
             Tumors(RECIST) criteria or who have evaluable lesion

         11. Patients with only bone lesion will be acceptable if the osteolytic lesion has a
             measurable soft tissue component by MRI or CT

         12. No influence on protocol treatment is considered in case prior therapy or
             examination.

         13. Adequate following organ function within 2 weeks before starting treatment. The
             latest examination results should be adopted and blood transfusion or treatment of
             hematopoietic factor drugs is not allowed 2 weeks before examination.

               -  Absolute neutrophil count &gt;= 1500 /mm3 or white blood cell(WBC) count &gt;= 3000
                  /mm3

               -  Platelets &gt;=10 x 10000 /mm3

               -  Hb &gt;= 9 g/dL

               -  Total bilirubin &lt;= 1.5 mg/dL

               -  aspartate aminotransferase(AST) and alanine aminotransferase(ALT) &lt;= 100
                  international unit(IU)/L

               -  Serum creatinine &lt;= 1.5 mg/dL

               -  Urine dipstick for proteinuria &lt;= 1+

         14. Written informed consent signed by patients before completing any treatment related
             procedure
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masakazu Toi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyoto University, Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shigehira Saji, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyoto University, Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shigehira Saji, MD, PhD</last_name>
    <phone>+81-75-751-4950</phone>
    <email>ssaji@kuhp.kyoto-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Japan Breast Cancer Research Group</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+81-3-6659-7723</phone>
      <email>office@jbcrg.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>November 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
